[4] [6] Ascorbic Acid (Vitamin C) Injection is contraindicated in individuals with a known hypersensitivity to ascorbic acid or any component of the formulation
The frequency and severity of gastrointestinal symptoms can vary depending on the formulation (tablets, sublingual preparations, or liquid forms), the dose administered, and individual patient factors such as existing digestive conditions or sensitivities to inactive ingredients in the supplement
These findings, however, come from animal and in-vitro models, and results in such models do not necessarily translate to humans
Final Thoughts BPC-157 remains one of the most intriguing peptides currently being studied in regenerative medicine
The specific thresholds that should prompt dose reduction or discontinuation include: ALT or AST elevation exceeding 3 times the patient's baseline value, new or worsening coagulopathy (INR increase of 0.5 or more from baseline), albumin decline below 2.5 g/dL, or new clinical signs of hepatic decompensation such as worsening ascites, encephalopathy, or jaundice [5]